UK Penny Stocks To Watch In July 2026

The UK market has recently faced challenges, with the FTSE 100 index closing lower due to weak trade data from China, highlighting ongoing global economic uncertainties. Despite these broader market pressures, investors might find opportunities in penny stocks—an investment area that remains relevant despite its somewhat outdated name. These smaller or newer companies can offer a unique combination of value and growth potential when backed by strong financials, making them an intriguing option for those looking to uncover hidden value amidst current market conditions.

We'll examine a selection from our screener results.

Ashmore Group (LSE:ASHM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Ashmore Group plc is a publicly owned investment manager with a market cap of £1.40 billion.

Operations: The company generates £132.4 million from its investment management services.

Market Cap: £1.4B

Ashmore Group, with a market cap of £1.40 billion and revenue of £132.4 million, has shown significant recent earnings growth of 56.3%, outpacing the industry average. Despite this, its earnings have declined by 22.4% annually over five years and are forecast to decrease by an average of 21.8% per year for the next three years. The company is debt-free with strong asset coverage for liabilities but faces challenges such as high non-cash earnings and a dividend yield not well supported by cash flows or profits. Recent insider selling may also be a concern for potential investors.

• Jump into the full analysis health report here for a deeper understanding of Ashmore Group.
• Assess Ashmore Group's future earnings estimates with our detailed growth reports.

Integrated Diagnostics Holdings (LSE:IDHC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Integrated Diagnostics Holdings plc is a consumer healthcare company that offers medical diagnostics services to patients, with a market cap of $301.13 million.

Operations: The company generates revenue through its Walk-In Segment, which contributed EGP 2.74 billion, and its Contract Segment, which brought in EGP 5.60 billion.

Market Cap: $301.13M

Integrated Diagnostics Holdings plc, with a market cap of $301.13 million, is trading at a significant discount to its estimated fair value and shows strong financial health with short-term assets exceeding both short and long-term liabilities. The company's earnings have grown by 58% over the past year, outpacing the healthcare industry average. Recent developments include a proposed acquisition by Moamena Abdul Wahab Kamel and Hend El Sherbini for approximately $150 million, potentially impacting liquidity due to plans to delist from the London Stock Exchange. Despite increased debt levels over five years, cash flow sufficiently covers existing debt obligations.

• Click here and access our complete financial health analysis report to understand the dynamics of Integrated Diagnostics Holdings.
• Evaluate Integrated Diagnostics Holdings' prospects by accessing our earnings growth report.

McBride (LSE:MCB)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: McBride plc manufactures and sells private label household and personal care products to retailers and brand owners across Europe, the Asia-Pacific, and internationally, with a market cap of £286.66 million.

Operations: The company's revenue is primarily generated from its Liquids segment (£529.7 million), followed by Unit Dosing (£226.5 million), Powders (£86.4 million), Aerosols (£64.1 million), and the Asia Pacific region (£23.6 million).

Market Cap: £286.66M

McBride plc, with a market cap of £286.66 million, presents a mixed picture as an investment in the penny stock category. The company trades at 51.5% below its estimated fair value and offers high-quality earnings despite recent negative growth of -25.5%. Debt levels remain high with a net debt to equity ratio of 115.8%, though operating cash flow covers 38.4% of this debt, indicating reasonable financial management. The board and management are seasoned, averaging over five years in tenure, which can provide stability amid volatility in profit margins and short-term liabilities exceeding assets by £14.8 million (£303.1M vs £288.3M).

• Navigate through the intricacies of McBride with our comprehensive balance sheet health report here.
• Understand McBride's earnings outlook by examining our growth report.

Where To Now?

• Navigate through the entire inventory of 275 UK Penny Stocks here.
• Ready To Venture Into Other Investment Styles? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com